Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
Aleix Prat(Hospital Clínic de Barcelona), Charles M. Perou(University of North Carolina at Chapel Hill), Lance D. Miller(Wake Forest University), Lisa A. Carey(University of North Carolina at Chapel Hill), Joel S. Parker(University of North Carolina at Chapel Hill), Matthew J. Ellis(Guardant (United States)), Torsten O. Nielsen(University of British Columbia), Jonas Bergh(Karolinska Institutet), Stephen Chia(BC Cancer Agency), Maggie C.U. Cheang(Institute of Cancer Research), Cheng Fan(University of North Carolina at Chapel Hill), Philip S. Bernard(University of Utah)
Cited by 141
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k